159 related articles for article (PubMed ID: 27717004)
21. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of somatic mutation in unexplained blood cytopenia.
Malcovati L; Gallì A; Travaglino E; Ambaglio I; Rizzo E; Molteni E; Elena C; Ferretti VV; Catricalà S; Bono E; Todisco G; Bianchessi A; Rumi E; Zibellini S; Pietra D; Boveri E; Camaschella C; Toniolo D; Papaemmanuil E; Ogawa S; Cazzola M
Blood; 2017 Jun; 129(25):3371-3378. PubMed ID: 28424163
[TBL] [Abstract][Full Text] [Related]
23. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
24. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
25. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
Song J; Hussaini M; Qin D; Zhang X; Shao H; Zhang L; Gajzer D; Basra P; Moscinski L; Zhang H
Am J Clin Pathol; 2020 Jun; 154(1):48-56. PubMed ID: 32112088
[TBL] [Abstract][Full Text] [Related]
26. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
[TBL] [Abstract][Full Text] [Related]
27. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
28. [The cause of cytopenia of undetermined significance can often be found by using next generation sequencing].
Hansen JW; Husby S; Grønbæk K
Ugeskr Laeger; 2017 Jun; 179(25):. PubMed ID: 28648154
[TBL] [Abstract][Full Text] [Related]
29. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
30. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
[TBL] [Abstract][Full Text] [Related]
31. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
32. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
33. ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.
Andréasson B; Pettersson H; Wasslavik C; Johansson P; Palmqvist L; Asp J
Br J Haematol; 2020 Jun; 189(5):913-919. PubMed ID: 32066200
[TBL] [Abstract][Full Text] [Related]
34. TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes.
Hu J; Xu J; Tian T; Xie J; Fan L; Zhu G; Xia T; Chen X; Tan Y; Chen X; Ren F; Zhang Y; Wang H; Xu Z
Blood Cells Mol Dis; 2019 Feb; 74():44-50. PubMed ID: 30454965
[TBL] [Abstract][Full Text] [Related]
35. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
36. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
37. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
38. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract][Full Text] [Related]
39. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
[TBL] [Abstract][Full Text] [Related]
40. Invariant phenotype and molecular association of biallelic
Awada H; Nagata Y; Goyal A; Asad MF; Patel B; Hirsch CM; Kuzmanovic T; Guan Y; Przychodzen BP; Aly M; Adema V; Shen W; Williams L; Nazha A; Abazeed ME; Sekeres MA; Radivoyevitch T; Haferlach T; Jha BK; Visconte V; Maciejewski JP
Blood Adv; 2019 Feb; 3(3):339-349. PubMed ID: 30709865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
